Encompass Health reports results for third quarter 2025
Increases full-year guidance
BIRMINGHAM, Ala., Oct. 29, 2025 /PRNewswire/ -- Encompass Health Corporation (NYSE: EHC), the largest owner and operator of inpatient rehabilitation hospitals in the United States, today reported its results of operations for the third quarter ended September 30, 2025.
Summary results
| | | | | | Growth | ||
| | Q3 2025 | | Q3 2024 | | Dollars | | Percent |
| | (In Millions, Except Per Share Data) | ||||||
| Net operating revenue | $ 1,477.5 | | $ 1,351.0 | | $ 126.5 | | 9.4 % |
| Income from continuing operations attributable to | 1.24 | | 1.07 | | 0.17 | | 15.9 % |
| Adjusted earnings per share | 1.23 | | 1.03 | | 0.20 | | 19.4 % |
| Cash flows provided by operating activities | 270.8 | | 267.8 | | 3.0 | | 1.1 % |
| Adjusted EBITDA | 300.1 | | 269.3 | | 30.8 | | 11.4 % |
| Adjusted free cash flow | 174.2 | | 189.7 | | (15.5) | | (8.2) % |
| | | | | | | | |
| (Actual Amounts) | | | | | | ||
| Discharges | 65,839 | | 62,715 | | | | 5.0 % |
| Same-store discharge growth | | | | | | | 2.9 % |
| Net patient revenue per discharge | $ 21,679 | | $ 20,987 | | | | 3.3 % |
See attached supplemental information for calculations of non-GAAP measures and reconciliations to their most comparable GAAP measure.
"During the quarter, we further increased our capacity to serve patients in need of inpatient rehabilitation care by opening three new hospitals and adding 39 beds to existing hospitals," said President and Chief Executive Officer Mark Tarr. "Our new hospitals include our first in Connecticut, a 40-bed hospital in Danbury; a 50-bed hospital in Daytona Beach, Florida; and a 50-bed hospital in Wildwood, Florida (The Villages). Our value proposition and operating strategy continue to be validated and we remain highly optimistic about the long-term prospects of our business."
Tarr added, "Encompass Health was recently named 'America's Most Awarded Leader in Inpatient Rehabilitation' by Newsweek and Statista for the sixth consecutive year. Our consistent presence on this prestigious list reflects our long-standing commitment to delivering high-quality patient care and excellent outcomes."
2025 Guidance
The Company increased its full-year guidance as follows:
| | Full-Year 2025 Guidance | ||
| | Previous Guidance | | Updated Guidance |
| | (In Millions, Except Per Share Data) | ||
| Net operating revenue | $5,880 to $5,980 | | $5,905 to $5,955 |
| Adjusted EBITDA | $1,220 to $1,250 | | $1,235 to $1,255 |
| Adjusted earnings per share from continuing operations | $5.12 to $5.34 | | $5.22 to $5.37 |
For considerations regarding the Company's 2025 guidance, see the supplemental information posted on the Company's website at http://investor.encompasshealth.com. See also the "Other information" section below for an explanation of why the Company does not provide guidance for comparable GAAP measures for Adjusted EBITDA and adjusted earnings per share.
Earnings conference call and webcast
The Company will host an investor conference call at 10:00 a.m. Eastern Time on Thursday, October 30, 2025 to discuss its results for the third quarter of 2025. For reference during the call, the Company will post certain supplemental information at http://investor.encompasshealth.com.
The conference call may be accessed by dialing 800 245-3047 and giving the conference ID EHCQ325. International callers should dial 203 518-9765 and give the same conference ID. Please call approximately ten minutes before the start of the call to ensure you are connected. The conference call will also be webcast live and will be available for on-line replay at http://investor.encompasshealth.com by clicking on an available link.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 171 hospitals in 39 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is named America's Most Awarded Leader in Inpatient Rehabilitation by Newsweek and Statista and is ranked among Fortune's World's Most Admired Companies™ and Forbes' Most Trusted Companies in America.1 For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
| 1 Fortune © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is a trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license. |
Other information
The information in this press release is summarized and should be read in conjunction with the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the "September 2025 Form 10-Q"), when filed, as well as the Company's Current Report on Form 8-K filed on October 29, 2025 (the "Q3 Earnings Form 8-K"), to which this press release is attached as Exhibit 99.1. In addition, the Company will post supplemental information today on its website at http://investor.encompasshealth.com for reference during its October 30, 2025 earnings call.
The financial data contained in the press release and supplemental information include non-GAAP financial measures, including the Company's adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow. Reconciliations to their most comparable GAAP measure, except with regard to non-GAAP guidance, are included below or in the Q3 Earnings Form 8-K. Readers are encouraged to review the "Note Regarding Presentation of Non-GAAP Financial Measures" included in the Q3 Earnings Form 8-K which provides further explanation and disclosure regarding the Company's use of these non-GAAP financial measures.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be not indicative of its ongoing operations. These items cannot be reasonably predicted and will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP.
However, the following reasonably estimable GAAP measures for 2025 would be included in a reconciliation for Adjusted EBITDA if the other reconciling GAAP measures could be reasonably predicted:
- Interest expense and amortization of debt discounts and fees - approximately $125 million
- Amortization of debt-related items - approximately $10 million
The Q3 Earnings Form 8-K and, when filed, the September 2025 Form 10-Q can be found on the Company's website at http://investor.encompasshealth.com and the SEC's website at www.sec.gov.
| Encompass Health Corporation and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited) | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| | (In Millions, Except Per Share Data) | ||||||
| Net operating revenues | $ 1,477.5 | | $ 1,351.0 | | $ 4,390.6 | | $ 3,968.2 |
| Operating expenses: | | | | | | | |
| Salaries and benefits | 784.8 | | 732.1 | | 2,314.8 | | 2,144.2 |
| Other operating expenses | 231.1 | | 202.4 | | 662.4 | | 596.2 |
| Occupancy costs | 14.9 | | 14.4 | | 44.5 | | 42.6 |
| Supplies | 64.6 | | 60.6 | | 189.9 | | 176.7 |
| General and administrative expenses | 56.1 | | 54.0 | | 167.8 | | 154.7 |
| Depreciation and amortization | 82.4 | | 78.4 | | 241.5 | | 221.6 |
| Total operating expenses | 1,233.9 | | 1,141.9 | | 3,620.9 | | 3,336.0 |
| Loss on early extinguishment of debt | — | | 0.4 | | — | | 0.4 |
| Interest expense and amortization of debt discounts and fees | 30.8 | | 34.9 | | 93.0 | | 104.4 |
| Other income | (5.9) | | (9.3) | | (15.1) | | (18.0) |
| Equity in net income of nonconsolidated affiliates | (1.2) | | (0.7) | | (3.5) | | (2.8) |
| Income from continuing operations before income tax expense | 219.9 | | 183.8 | | 695.3 | | 548.2 |
| Provision for income tax expense | 44.9 | | 36.0 | | 137.5 | | 112.6 |
| Income from continuing operations | 175.0 | | 147.8 | | 557.8 | | 435.6 |
| Loss from discontinued operations, net of tax | (0.4) | | (0.7) | | (1.8) | | (3.2) |
| Net income | 174.6 | | 147.1 | | 556.0 | | 432.4 |
| Less: Net income attributable to noncontrolling interests | (48.1) | | (38.9) | | (135.9) | | (97.6) |
| Net income attributable to Encompass Health | $ 126.5 | | $ 108.2 | | $ 420.1 | | $ 334.8 |
| | | | | | | | |
| Weighted average common shares outstanding: | | | | | | | |
| Basic | 100.5 | | 99.9 | | 100.5 | | 99.9 |
| Diluted | 102.3 | | 102.1 | | 102.3 | | 102.2 |
| Earnings per common share: | | | | | | | |
| Basic earnings per share attributable to Encompass | | | | | | | |
| Continuing operations | $ 1.26 | | $ 1.09 | | $ 4.19 | | $ 3.36 |
| Discontinued operations | — | | (0.01) | | (0.02) | | (0.03) |
| Net income | $ 1.26 | | $ 1.08 | | $ 4.17 | | $ 3.33 |
| Diluted earnings per share attributable to Encompass | | | | | | | |
| Continuing operations | $ 1.24 | | $ 1.07 | | $ 4.13 | | $ 3.31 |
| Discontinued operations | — | | (0.01) | | (0.02) | | (0.03) |
| Net income | $ 1.24 | | $ 1.06 | | $ 4.11 | | $ 3.28 |
| | | | | | | | |
| Amounts attributable to Encompass Health common shareholders: | | | | | | | |
| Income from continuing operations | $ 126.9 | | $ 108.9 | | $ 421.9 | | $ 338.0 |
| Loss from discontinued operations, net of tax | (0.4) | | (0.7) | | (1.8) | | (3.2) |
| Net income attributable to Encompass Health | $ 126.5 | | $ 108.2 | | $ 420.1 | | $ 334.8 |
| Encompass Health Corporation and Subsidiaries Condensed Consolidated Balance Sheets (Unaudited) | |||
| | |||
| | September 30, | | December 31, |
| | (In Millions) | ||
| Assets | | | |
| Current assets: | | | |
| Cash and cash equivalents | $ 48.7 | | $ 85.4 |
| Restricted cash | 45.0 | | 37.7 |
| Accounts receivable | 610.8 | | 598.8 |
| Other current assets | 165.3 | | 165.0 |
| Total current assets | 869.8 | | 886.9 |
| Property and equipment, net | 3,925.5 | | 3,643.1 |
| Operating lease right-of-use assets | 218.1 | | 203.7 |
| Goodwill | 1,303.0 | | 1,284.0 |
| Intangible assets, net | 291.9 | | 297.8 |
| Other long-term assets | 257.4 | | 219.2 |
| Total assets | $ 6,865.7 | | $ 6,534.7 |
| Liabilities and Shareholders' Equity | | | |
| Current liabilities: | | | |
| Current portion of long-term debt | $ 39.0 | | $ 138.6 |
| Current operating lease liabilities | 25.9 | | 26.3 |
| Accounts payable | 138.4 | | 171.0 |
| Accrued expenses and other current liabilities | 558.7 | | 505.1 |
| Total current liabilities | 762.0 | | 841.0 |
| Long-term debt, net of current portion | 2,393.9 | | 2,359.2 |
| Long-term operating lease liabilities | 202.8 | | 189.7 |
| Deferred income tax liabilities | 107.5 | | 105.2 |
| Other long-term liabilities | 213.2 | | 190.4 |
| Total liabilities | 3,679.4 | | 3,685.5 |
| Commitments and contingencies | | | |
| Redeemable noncontrolling interests | 54.4 | | 56.5 |
| Shareholders' equity: | | | |
| Encompass Health shareholders' equity | 2,373.8 | | 2,067.0 |
| Noncontrolling interests | 758.1 | | 725.7 |
| Total shareholders' equity | 3,131.9 | | 2,792.7 |
| Total liabilities and shareholders' equity | $ 6,865.7 | | $ 6,534.7 |
| Encompass Health Corporation and Subsidiaries Condensed Consolidated Statements of Cash Flows (Unaudited) | |||
| | |||
| | Nine Months Ended | ||
| | 2025 | | 2024 |
| | (In Millions) | ||
| Cash flows from operating activities: | | | |
| Net income | $ 556.0 | | $ 432.4 |
| Loss from discontinued operations, net of tax | 1.8 | | 3.2 |
| Adjustments to reconcile net income to net cash provided by operating activities— | | | |
| Depreciation and amortization | 241.5 | | 221.6 |
| Stock-based compensation | 38.1 | | 35.8 |
| Deferred tax expense | 3.2 | | 2.1 |
| Other, net | 1.1 | | 13.5 |
| Change in assets and liabilities, net of acquisitions— | | | |
| Accounts receivable | (18.8) | | 29.1 |
| Other assets | (19.5) | | (43.3) |
| Accounts payable | (32.7) | | 1.4 |
| Accrued payroll | 6.4 | | (2.6) |
| Accrued interest payable | (15.8) | | (19.2) |
| Other liabilities | 70.8 | | 53.7 |
| Net cash used in operating activities of discontinued operations | (2.5) | | (3.7) |
| Total adjustments | 271.8 | | 288.4 |
| Net cash provided by operating activities | 829.6 | | 724.0 |
| Cash flows from investing activities: | | | |
| Purchases of property, equipment, and intangible assets | (507.1) | | (443.8) |
| Proceeds from sale of restricted investments | 160.0 | | 17.9 |
| Purchases of restricted investments | (165.9) | | (20.0) |
| Other, net | (12.2) | | (3.7) |
| Net cash used in investing activities | (525.2) | | (449.6) |
| Cash flows from financing activities: | | | |
| Principal payments on debt, including pre-payments | (113.2) | | (153.4) |
| Principal borrowings on notes | — | | 15.0 |
| Borrowings on revolving credit facility | 140.0 | | 50.0 |
| Payments on revolving credit facility | (80.0) | | (50.0) |
| Principal payments under finance lease obligations | (17.7) | | (16.2) |
| Repurchases of common stock, including fees and expenses | (81.7) | | (23.6) |
| Dividends paid on common stock | (52.1) | | (45.8) |
| Distributions paid to noncontrolling interests of consolidated affiliates | (109.4) | | (85.5) |
| Taxes paid on behalf of employees for shares withheld | (19.9) | | (12.1) |
| Contributions from noncontrolling interests of consolidated affiliates | — | | 139.7 |
| Other, net | 0.2 | | 2.2 |
| Net cash used in financing activities | (333.8) | | (179.7) |
| (Decrease) increase in cash, cash equivalents, and restricted cash | (29.4) | | 94.7 |
| Cash, cash equivalents, and restricted cash at beginning of period | 123.1 | | 104.2 |
| Cash, cash equivalents, and restricted cash at end of period | $ 93.7 | | $ 198.9 |
| Encompass Health Corporation and Subsidiaries Supplemental Information Earnings Per Share | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| | (In Millions, Except Per Share Data) | ||||||
| Adjusted EBITDA | $ 300.1 | | $ 269.3 | | $ 932.3 | | $ 814.1 |
| Depreciation and amortization | (82.4) | | (78.4) | | (241.5) | | (221.6) |
| Interest expense and amortization of debt discounts | (30.8) | | (34.9) | | (93.0) | | (104.4) |
| Stock-based compensation | (14.3) | | (12.9) | | (38.1) | | (35.8) |
| Loss on disposal or impairment of assets | (1.9) | | (0.6) | | (2.4) | | (11.3) |
| | 170.7 | | 142.5 | | 557.3 | | 441.0 |
| Items not indicative of ongoing operating performance: | | | | | | | |
| Loss on early extinguishment of debt | — | | (0.4) | | — | | (0.4) |
| Change in fair market value of marketable securities | 1.1 | | 2.8 | | 2.1 | | 2.7 |
| Asset impairment impact on noncontrolling interests | — | | — | | — | | 7.3 |
| Pre-tax income | 171.8 | | 144.9 | | 559.4 | | 450.6 |
| Income tax expense | (44.9) | | (36.0) | | (137.5) | | (112.6) |
| Income from continuing operations (1) | $ 126.9 | | $ 108.9 | | $ 421.9 | | $ 338.0 |
| | | | | | | | |
| Basic shares | 100.5 | | 99.9 | | 100.5 | | 99.9 |
| Diluted shares | 102.3 | | 102.1 | | 102.3 | | 102.2 |
| | | | | | | | |
| Basic earnings per share (1) | $ 1.26 | | $ 1.09 | | $ 4.19 | | $ 3.36 |
| Diluted earnings per share (1) | $ 1.24 | | $ 1.07 | | $ 4.13 | | $ 3.31 |
| |
| (1) Income from continuing operations attributable to Encompass Health |
| Encompass Health Corporation and Subsidiaries Supplemental Information Adjusted Earnings Per Share | |||||||
| | |||||||
| | Q3 | | 9 Months | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| | | | | | | | |
| Earnings per share, as reported | $ 1.24 | | $ 1.07 | | $ 4.13 | | $ 3.31 |
| Adjustments, net of tax: | | | | | | | |
| Asset impairment impact | — | | — | | — | | 0.02 |
| Income tax adjustments | — | | (0.02) | | (0.12) | | (0.05) |
| Change in fair market value of marketable securities | (0.01) | | (0.02) | | (0.01) | | (0.02) |
| Adjusted earnings per share* | $ 1.23 | | $ 1.03 | | $ 3.99 | | $ 3.26 |
| |
| * Adjusted EPS may not sum due to rounding. |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| | (In Millions) | ||||||
| Net cash provided by operating activities | $ 270.8 | | $ 267.8 | | $ 829.6 | | $ 724.0 |
| Interest expense and amortization of debt discounts and fees | 30.8 | | 34.9 | | 93.0 | | 104.4 |
| Gain on sale of investments, excluding impairments | 3.0 | | 4.6 | | 6.2 | | 5.8 |
| Equity in net income of nonconsolidated affiliates | 1.2 | | 0.7 | | 3.5 | | 2.8 |
| Net income attributable to noncontrolling interests in | (48.1) | | (38.9) | | (135.9) | | (97.6) |
| Amortization of debt-related items | (2.4) | | (2.4) | | (7.2) | | (7.3) |
| Distributions from nonconsolidated affiliates | — | | (1.1) | | (1.4) | | (3.1) |
| Current portion of income tax expense | 47.0 | | 38.1 | | 134.3 | | 110.5 |
| Change in assets and liabilities | (1.8) | | (32.5) | | 9.6 | | (19.1) |
| Cash used in operating activities of discontinued operations | 0.6 | | 1.0 | | 2.5 | | 3.7 |
| Asset impairment impact on noncontrolling interests | — | | — | | — | | (7.3) |
| Change in fair market value of marketable securities | (1.1) | | (2.8) | | (2.1) | | (2.7) |
| Other | 0.1 | | (0.1) | | 0.2 | | — |
| Adjusted EBITDA | $ 300.1 | | $ 269.3 | | $ 932.3 | | $ 814.1 |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share | ||||||||
| | ||||||||
| | For the Three Months Ended September 30, 2025 | |||||||
| | | | Adjustments | | | |||
| | As | | | Income Tax | | Change in Fair | | As |
| | (In Millions, Except Per Share Amounts) | |||||||
| Adjusted EBITDA* | $ 300.1 | | | $ — | | $ — | | $ 300.1 |
| Depreciation and amortization | (82.4) | | | — | | — | | (82.4) |
| Interest expense and amortization of debt discounts and fees | (30.8) | | | — | | — | | (30.8) |
| Stock-based compensation | (14.3) | | | — | | — | | (14.3) |
| Loss on disposal or impairment of assets | (1.9) | | | — | | — | | (1.9) |
| Change in fair market value of marketable securities | 1.1 | | | — | | (1.1) | | — |
| Income from continuing operations before income tax expense | 171.8 | | | — | | (1.1) | | 170.7 |
| Provision for income tax expense | (44.9) | | | (0.2) | | 0.3 | | (44.8) |
| Income from continuing operations attributable to Encompass Health | $ 126.9 | | | $ (0.2) | | $ (0.8) | | $ 125.9 |
| Diluted earnings per share from continuing operations** | $ 1.24 | | | $ — | | $ (0.01) | | $ 1.23 |
| Diluted shares used in calculation | 102.3 | | | | | | | |
| |
| * See reconciliation of net income to Adjusted EBITDA. |
| ** Adjusted EPS may not sum across due to rounding. |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share | |||||||||
| | |||||||||
| | For the Three Months Ended September 30, 2024 | ||||||||
| | | | Adjustments | | | ||||
| | As | | Loss on | | Income Tax | | Change in Fair | | As |
| | (In Millions, Except Per Share Amounts) | ||||||||
| Adjusted EBITDA* | $ 269.3 | | $ — | | $ — | | $ — | | $ 269.3 |
| Depreciation and amortization | (78.4) | | — | | — | | — | | (78.4) |
| Interest expense and amortization of debt discounts and fees | (34.9) | | — | | — | | — | | (34.9) |
| Stock-based compensation | (12.9) | | — | | — | | — | | (12.9) |
| Loss on disposal or impairment of assets | (0.6) | | — | | — | | — | | (0.6) |
| Loss on early extinguishment of debt | (0.4) | | 0.4 | | — | | — | | — |
| Change in fair market value of marketable securities | 2.8 | | — | | — | | (2.8) | | — |
| Income from continuing operations before income tax expense | 144.9 | | 0.4 | | — | | (2.8) | | 142.5 |
| Provision for income tax expense | (36.0) | | (0.1) | | (2.1) | | 0.7 | | (37.5) |
| Income from continuing operations attributable to Encompass Health | $ 108.9 | | $ 0.3 | | $ (2.1) | | $ (2.1) | | $ 105.0 |
|
Diluted earnings per share from continuing operations** | $ 1.07 | | $ — | | $ (0.02) | | $ (0.02) | | $ 1.03 |
|
Diluted shares used in calculation | 102.1 | | | | | | | | |
| |
| * See reconciliation of net income to Adjusted EBITDA. |
| ** Adjusted EPS may not sum across due to rounding. |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share | |||||||
| | |||||||
| | For the Nine Months Ended September 30, 2025 | ||||||
| | | | Adjustments | | | ||
| | As | | Income Tax | | Change in Fair | | As |
| | (In Millions, Except Per Share Amounts) | ||||||
| Adjusted EBITDA* | $ 932.3 | | $ — | | $ — | | $ 932.3 |
| Depreciation and amortization | (241.5) | | — | | — | | (241.5) |
| Interest expense and amortization of debt discounts and fees | (93.0) | | — | | — | | (93.0) |
| Stock-based compensation | (38.1) | | — | | — | | (38.1) |
| Loss on disposal or impairment of assets | (2.4) | | — | | — | | (2.4) |
| Change in fair market value of marketable securities | 2.1 | | — | | (2.1) | | — |
| Income from continuing operations before income tax expense | 559.4 | | — | | (2.1) | | 557.3 |
| Provision for income tax expense | (137.5) | | (11.8) | | 0.6 | | (148.7) |
| Income from continuing operations attributable to Encompass Health | $ 421.9 | | $ (11.8) | | $ (1.5) | | $ 408.6 |
| Diluted earnings per share from continuing operations** | $ 4.13 | | $ (0.12) | | $ (0.01) | | $ 3.99 |
| Diluted shares used in calculation | 102.3 | | | | | | |
| |
| * See reconciliation of net income to Adjusted EBITDA. |
| ** Adjusted EPS may not sum across due to rounding. |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Income from Continuing Operations Attributable to Encompass Health per Diluted Share to Adjusted Earnings Per Share | |||||||||||
| | |||||||||||
| | For the Nine Months Ended September 30, 2024 | ||||||||||
| | | | Adjustments | | | ||||||
| | As | | Asset | | Loss on | | Income Tax | | Change in Fair | | As |
| | (In Millions, Except Per Share Amounts) | ||||||||||
| Adjusted EBITDA* | $ 814.1 | | $ — | | $ — | | $ — | | $ — | | $ 814.1 |
| Depreciation and amortization | (221.6) | | — | | — | | — | | — | | (221.6) |
| Interest expense and amortization of debt discounts and fees | (104.4) | | — | | — | | — | | — | | (104.4) |
| Stock-based compensation | (35.8) | | — | | — | | — | | — | | (35.8) |
| Loss on disposal or impairment of assets | (11.3) | | 10.4 | | — | | — | | — | | (0.9) |
| Loss on early extinguishment of debt | (0.4) | | — | | 0.4 | | — | | — | | — |
| Change in fair market value of marketable securities | 2.7 | | — | | — | | — | | (2.7) | | — |
| Asset impairment impact on noncontrolling interests | 7.3 | | (7.3) | | — | | — | | — | | — |
| Income from continuing operations before income tax expense | 450.6 | | 3.1 | | 0.4 | | — | | (2.7) | | 451.4 |
| Provision for income tax expense | (112.6) | | (1.3) | | (0.1) | | (5.1) | | 0.7 | | (118.4) |
| Income from continuing operations attributable to Encompass Health | $ 338.0 | | $ 1.8 | | $ 0.3 | | $ (5.1) | | $ (2.0) | | $ 333.0 |
|
Diluted earnings per share from continuing operations** | $ 3.31 | | $ 0.02 | | $ — | | $ (0.05) | | $ (0.02) | | $ 3.26 |
|
Diluted shares used in calculation | 102.2 | | | | | | | | | | |
| |
| * See reconciliation of net income to Adjusted EBITDA. |
| ** Adjusted EPS may not sum across due to rounding. |
| Encompass Health Corporation and Subsidiaries Supplemental Information Reconciliation of Net Income to Adjusted EBITDA | |||||||
| | |||||||
| | Three Months Ended | | Nine Months Ended | ||||
| | 2025 | | 2024 | | 2025 | | 2024 |
| | (In Millions) | ||||||
| Net income | $ 174.6 | | $ 147.1 | | $ 556.0 Für dich aus unserer Redaktion zusammengestelltHinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. Weitere Artikel des AutorsThemen im Trend | ||